Evidence map›Paper›PMID 35754779›Full record

ArticleAdvanced nanobiomed research2022

Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Chunhong Dong, Bao-Zhong Wang

Open access · goldAbstract read
In one paragraph

Article in Advanced nanobiomed research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chunhong DongCenter for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia 30303, USA.
Bao-Zhong WangCenter for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, Georgia 30303, USA.
Georgia State University · US

Funding

Novel Influenza nano vaccines for broad cross protectionR01AI101047 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2012 to 2023
$6.1M
Multivalent nanocluster universal influenza vaccine given by microneedle patchR01AI143844 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2019 to 2023
$3.9M
Novel vaccine to enhance breadth of influenza immunity by skin vaccinationR01AI116835 · NIAID · GEORGIA STATE UNIVERSITY · PI WANG, BAOZHONG · 2015 to 2018
$2.4M
NIAID NIH HHS R01 AI101047NIAID NIH HHS R01 AI116835NIAID NIH HHS R01 AI143844
6 · The paper itself

Abstract

Reoccurring seasonal flu epidemics and occasional pandemics are among the most severe threats to public health. Current seasonal influenza vaccines provide limited protection against drifted circulating strains and no protection against influenza pandemics. Next-generation influenza vaccines, designated as universal influenza vaccines, should be safe, affordable, and elicit long-lasting cross-protective influenza immunity. Nanotechnology plays a critical role in the development of such novel vaccines. Engineered nanoparticles can incorporate multiple advantageous properties into the same nanoparticulate platforms to improve vaccine potency and breadth. These immunological properties include virus-like biomimicry, high antigen-load, controlled antigen release, targeted delivery, and induction of innate signaling pathways. Many nanoparticle influenza vaccines have shown promising results in generating potent and broadly protective immune responses. This review will summarize the necessity and characteristics of next-generation influenza vaccines and the immunological correlates of broad influenza immunity and focus on how cutting-edge nanoparticle technology contributes to such vaccine development. The review will give new insights into the rational design of nanoparticle universal vaccines to combat influenza epidemics and pandemics.

Indexed as

cross-protectionnanoparticlesUniversal influenza vaccinesvaccine delivery

Identifiers

PMID35754779
PMCPMC9231845
OpenAlexW4200415449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.